TY  - GEN
N2  - Acute Myeloid Leukemia (AML) is a genetically and phenotypically heterogeneous white blood cell cancer with a poor prognosis and limited therapeutic options. For many decades the current standard of care has been an intensive chemotherapy regimen, to which only a fraction of patients respond and are physically able to withstand. However, the advent of deep genetic sequencing has led to the discovery of a number of mutational lesions targetable by small-molecule inhibitors, which more patients can tolerate. This dissertation demonstrates that AML drives in vivo T cell exhaustion, which is coordinated by multiple T cell receptor (TCR) activated transcription factors and BET proteins.
DO  - 10.6083/z890rt88b
DO  - DOI
AB  - Acute Myeloid Leukemia (AML) is a genetically and phenotypically heterogeneous white blood cell cancer with a poor prognosis and limited therapeutic options. For many decades the current standard of care has been an intensive chemotherapy regimen, to which only a fraction of patients respond and are physically able to withstand. However, the advent of deep genetic sequencing has led to the discovery of a number of mutational lesions targetable by small-molecule inhibitors, which more patients can tolerate. This dissertation demonstrates that AML drives in vivo T cell exhaustion, which is coordinated by multiple T cell receptor (TCR) activated transcription factors and BET proteins.
T1  - Targeting epigenetic dysregulation in acute myeloid leukemia via BET protein inhibition: mechanisms of resistance and contributions towards the anti-tumor response
DA  - 2022
AU  - Romine, Kyle
L1  - https://digitalcollections.ohsu.edu/record/9487/files/Romine.Kyle.2022.pdf
PB  - Oregon Health and Science University
PY  - 2022
ID  - 9487
L4  - https://digitalcollections.ohsu.edu/record/9487/files/Romine.Kyle.2022.pdf
KW  - Standard of Care
KW  - T-Lymphocytes
KW  - T-Cell Exhaustion
KW  - acute myeloid leukemia
KW  - brd4
KW  - epigenetics
TI  - Targeting epigenetic dysregulation in acute myeloid leukemia via BET protein inhibition: mechanisms of resistance and contributions towards the anti-tumor response
Y1  - 2022
L2  - https://digitalcollections.ohsu.edu/record/9487/files/Romine.Kyle.2022.pdf
LK  - https://digitalcollections.ohsu.edu/record/9487/files/Romine.Kyle.2022.pdf
UR  - https://digitalcollections.ohsu.edu/record/9487/files/Romine.Kyle.2022.pdf
ER  -